Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/5/2019
SIETES contiene 92751 citas

 
 
 1 a 20 de 165 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Bersoff-Matcha SJ, Chamberlain C, Cao C, Kortepeter C, Chong WH. Fournier gangrene associated with sodium–glucose cotransporter-2 inhibitors: a review of spontaneous postmarketing cases. Ann Intern Med 2019:7 de mayo. [Ref.ID 103108]
3. Cita con resumen
Keh D, Trips E, Marx G, Wirtz SP, Abduljawwad E, Bercker S, Bogatsch H, Briegel J, Engel C, Gerlach H, Goldmann A, Kuhn SO, Hüter L, Meier-Hellmann A, Nierhaus A, Kluge S, Lehmke J, Loeffler M, Oppert M, Resener K, Schädler D, Schuerholz T, Simon P, Weiler N, Weyland A, Reinhart K, Brunkhorst FM, SepNet-Critical Care Trials Group. Effect of hydrocortisone on development of shock among patients with severe sepsis: the HYPRESS randomized clinical trial. JAMA 2016;316:1775-85. [Ref.ID 100934]
4. Cita con resumen
Gordon AC, Mason AJ, Thirunavukkarasu N, Perkins GD, Cecconi M, Cepkova M, Pogson DG, Aya HD, Anjum A, Frazier GJ, Santhakumaran S, Ashby D, Brett SJ, for the VANISH Investigators. Effect of early vasopressin vs norepinephrine on kidney failure in patients with septic shock: the VANISH randomized clinical trial. JAMA 2016;316:509-18. [Ref.ID 100687]
5.Enlace a cita original Cita con resumen
Gotts JE, Matthay MA. Sepsis: pathophysiology and clinical management. BMJ 2016;353:i1585. [Ref.ID 100339]
6.
Seymour CW, Rosengart MR. Septic shock: advances in diagnosis and treatment. JAMA 2015;314:708-17. [Ref.ID 99498]
8.Tiene citas relacionadas
Morelli A, Ertmer C, Westphal M, Rehberg S, Kampmeier T, Ligges S, Orecchioni A, D'Egidio A, D'Ippoliti F, Raffone C, Venditti M, Guarracino F, Girardis M, Tritapepe L, Pietropaoli P, Mebazaa A, Singer M. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 2013;310:1683-91. [Ref.ID 96415]
9.Tiene citas relacionadas
Pinsky MR. Is there a role for ß-blockade in septic shock?. JAMA 2013;310:1677-8. [Ref.ID 96412]
10. Cita con resumen
Morelli A, Donati A, Ertmer C, Rehberg S, Kampmeier T, Orecchioni A, D'Egidio A, Cecchini V, Landoni G, Pietrapaoli P, Westphal M, Venditti M, Mebazaa A, Singer M. Microvascular effects of heart rate control with esmolol in patients with septic shock: a pilot study. Crit Care Med 2013;41:2162-8. [Ref.ID 95957]
11.Tiene citas relacionadas Cita con resumen
Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, Wetterslev J. Hydroxyethyl starch 130/0.38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ 2013;346:1212. [Ref.ID 95405]
12.Tiene citas relacionadas Cita con resumen
Prowle JR, Pearse RM. Is it the end of the road for synthetic starches in critical illness?. BMJ 2013;346:10. [Ref.ID 95404]
13.
Boyer A, Gruson D, Bouchet S, Clozeau B, Hoan-Nam B, Vargas F, Gilles H, Molimard M, Rogues A-M, Moore N. Aminoglycosides in septic shock - An overview, with specific consideration given to their nephrotoxic risk. Drug Saf 2013;36:217-30. [Ref.ID 95310]
14. Cita con resumen
Opal SM, Laterre P-F, Francois B, LaRosa SP, Angus DC, Mira J-P, Wittebole X, Dugemier T, Perrotin D, Tidswell M, Jauregui L, Krell K, Pachl J, Takahashi T, Peckelsen C, Cordasco E, Chang C-S, Oeyen S, Aikawa N, Maruyama T, Schein R, Kalil AC, Van Nuffelen M, Lynn M, Rossignol DP, Gogate J, Roberts MB, Wheeler JL, Vincent J-L, for the ACCESS Study Group. Effect of eritoran, an antagonist of MED2-TLR4, on mortality in patients with severe sepsis: the ACCESS randomized trial. JAMA 2013;309:1154-62. [Ref.ID 95110]
15.Tiene citas relacionadas
Wenzel RP, Edmond MB. Septic shock - Evaluating another failed treatment. N Engl J Med 2012;366:2122-4. [Ref.ID 93042]
16.Tiene citas relacionadas Cita con resumen
Ranieri VM, Thompson BT, Barie PS, Dhainaut J-F, Douglas IS, Finfer S, Gardlund B, Marshall JC, Rhodes A, Artigas A, Payen D, Tenhunen J, Al-Khaldi HR, Thompson V, Janes J, Macias WL, Vangerow B, Williams MD, for the PROWESS-SHOCK Study Group. Drotecogin alfa (activated) in adults with septic shock. N Engl J Med 2012;366:2055-64. [Ref.ID 93040]
17.
Suffredini AF, Munford RS. Novel therapies for septic shock over the past 4 decades. JAMA 2011;306:194. [Ref.ID 91390]
18.Enlace a cita original
Swoboda S, Ober MC, Lichtenstern C, Saleh S, Schwenger V, Sonntag HG, Haefeli WE, Hempel G, Hoppe-Tichy T, Weigand MA. Pharmacokinetics of linezolid in septic patients with and without extended dialysis. Eur J Clin Pharmacol 2010;66:marzo. [Ref.ID 88031]
19.Tiene citas relacionadas
Levy JH. Treating shock - Old drugs, new ideas. N Engl J Med 2010;362:841-3. [Ref.ID 87960]
20.Tiene citas relacionadas Cita con resumen
De Backer D, Biston P, Devriendt J, Madl C, Chochrad D, Aldecoa C, Brasseur A, Defrance P, Gottignies P, Vincent JL, for the SOAP Ii Investigators. Comparison of dopamine and norepinephrine in the treatment of shock. N Engl J Med 2010;362:779-89. [Ref.ID 87955]
Seleccionar todas
 
 1 a 20 de 165 siguiente >>